Scientists are working to establish the safety and efficacy of mRNA-based malaria vaccines. Clinical trials on the first mRNA-based malaria vaccine are set to start this year. Experts are optimistic of success but say research funding is critical.
After the success of mRNA vaccines against COVID-19, scientists are cautiously optimistic that the same technology can be used to tackle other widespread diseases such as malaria.
SEATTLE, Feb. 15, 2022 /PRNewswire/ According to Coherent Market Insights, the MR vaccines market is estimated to be valued at US$ 55.7 million in 2021 and is expected to exhibit a CAGR of
/PRNewswire/ According to Coherent Market Insights, the MR vaccines market is estimated to be valued at US$ 55.7 million in 2021 and is expected to exhibit.